Literature DB >> 19462421

Ulcerative colitis: correlation of the Rachmilewitz endoscopic activity index with fecal calprotectin, clinical activity, C-reactive protein, and blood leukocytes.

Alain M Schoepfer1, Christoph Beglinger, Alex Straumann, Michael Trummler, Pietro Renzulli, Frank Seibold.   

Abstract

BACKGROUND: The accuracy of noninvasive markers for the detection of endoscopically active ulcerative colitis (UC) according the Rachmilewitz Score is so far unknown. The aim was to evaluate the correlation between endoscopic disease activity and fecal calprotectin, Clinical Activity Index, C-reactive protein (CRP), and blood leukocytes.
METHODS: UC patients undergoing colonoscopy were prospectively enrolled and scored independently according the endoscopic and clinical part of the Rachmilewitz Index. Patients and controls provided fecal and blood samples for measuring calprotectin, CRP, and leukocytes.
RESULTS: Values in UC patients (n = 134) compared to controls (n = 48): calprotectin: 396 ± 351 versus 18.1 ± 5 μg/g, CRP 16 ± 13 versus 3 ± 2 mg/L, blood leukocytes 9.9 ± 3.5 versus 5.4 ± 1.9 g/L (all P < 0.001). Endoscopic disease activity correlated closest with calprotectin (Spearman's rank correlation coefficient r = 0.834), followed by Clinical Activity Index (r = 0.672), CRP (r = 0.503), and leukocytes (r = 0.461). Calprotectin levels were significantly lower in UC patients with inactive disease (endoscopic score 0-3, calprotectin 42 ± 38 μg/g), compared to patients with mild (score 4-6, calprotectin 210 ± 121 μg/g, P < 0.001), moderate (score 7-9, calprotectin 392 ± 246 μg/g, P = 0.002), and severe disease (score 10-12, calprotectin 730 ± 291 μg/g, P < 0.001). The overall accuracy for the detection of endoscopically active disease (score ≥4) was 89% for calprotectin, 73% for Clinical Activity Index, 62% for elevated CRP, and 60% for leukocytosis.
CONCLUSIONS: Fecal calprotectin correlated closest with endoscopic disease activity, followed by Clinical Activity Index, CRP, and blood leukocytes. Furthermore, fecal calprotectin was the only marker that reliably discriminated inactive from mild, moderate, and highly active disease, which emphasizes its usefulness for activity monitoring.
Copyright © 2009 Crohn's & Colitis Foundation of America, Inc.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19462421     DOI: 10.1002/ibd.20986

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  104 in total

1.  Fecal calprotectin and ulcerative colitis endoscopic activity index as indicators of mucosal healing in ulcerative colitis.

Authors:  Tarang Taghvaei; Iradj Maleki; Farshad Nagshvar; Hafez Fakheri; Vahid Hosseini; Seyed Mohammad Valizadeh; Hassan Neishaboori
Journal:  Intern Emerg Med       Date:  2014-11-04       Impact factor: 3.397

Review 2.  Mucosal healing in inflammatory bowel disease: where do we stand?

Authors:  Christina Ha; Asher Kornbluth
Journal:  Curr Gastroenterol Rep       Date:  2010-12

3.  Effectiveness and cost-effectiveness of measuring fecal calprotectin in diagnosis of inflammatory bowel disease in adults and children.

Authors:  Zhuo Yang; Nick Clark; K T Park
Journal:  Clin Gastroenterol Hepatol       Date:  2013-07-21       Impact factor: 11.382

Review 4.  Clinical implications of mucosal healing for the management of IBD.

Authors:  Guillaume Pineton de Chambrun; Laurent Peyrin-Biroulet; Marc Lémann; Jean-Frédéric Colombel
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2009-12-01       Impact factor: 46.802

5.  Ulcerative colitis patients in clinical remission demonstrate correlations between fecal immunochemical test results, mucosal healing, and risk of relapse.

Authors:  Asuka Nakarai; Jun Kato; Sakiko Hiraoka; Shiho Takashima; Daisuke Takei; Toshihiro Inokuchi; Yuusaku Sugihara; Masahiro Takahara; Keita Harada; Hiroyuki Okada
Journal:  World J Gastroenterol       Date:  2016-06-07       Impact factor: 5.742

6.  Soluble ST2: a new and promising activity marker in ulcerative colitis.

Authors:  David Díaz-Jiménez; Lucía E Núñez; Caroll J Beltrán; Enzo Candia; Cristóbal Suazo; Manuel Alvarez-Lobos; María-Julieta González; Marcela A Hermoso; Rodrigo Quera
Journal:  World J Gastroenterol       Date:  2011-05-07       Impact factor: 5.742

Review 7.  Noninvasive methods in evaluation of inflammatory bowel disease: where do we stand now? An update.

Authors:  Cansel Turkay; Benan Kasapoglu
Journal:  Clinics (Sao Paulo)       Date:  2010-02       Impact factor: 2.365

8.  Fecal calprotectin and the clinical activity index are both useful to monitor medical treatment in patients with ulcerative colitis.

Authors:  Emanuel Burri; Christoph Beglinger; Stefanie von Felten; Frank Serge Lehmann
Journal:  Dig Dis Sci       Date:  2014-10-26       Impact factor: 3.199

9.  Energy expenditure in Japanese patients with severe or moderate ulcerative colitis.

Authors:  Masaya Sasaki; Tomoko Johtatsu; Mika Kurihara; Hiromi Iwakawa; Toshihiro Tanaka; Shigeki Bamba; Tomoyuki Tsujikawa; Yoshihide Fujiyama; Akira Andoh
Journal:  J Clin Biochem Nutr       Date:  2010-04-23       Impact factor: 3.114

10.  Predictors of endoscopic inflammation in patients with ulcerative colitis in clinical remission.

Authors:  Laura Rosenberg; Garrett O Lawlor; Talia Zenlea; Jeffrey D Goldsmith; Anne Gifford; Kenneth R Falchuk; Jacqueline L Wolf; Adam S Cheifetz; Simon C Robson; Alan C Moss
Journal:  Inflamm Bowel Dis       Date:  2013 Mar-Apr       Impact factor: 5.325

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.